Since the release of imatinib mesylate (a.k.a. STI571, GleevecTM), an inhibitor of KIT and PDGFRA activation, the immunohistochemical demonstration of KIT immunoreactivity (-ir) has been essential for the diagnosis of GIST [3]. Here, KIT is linked to gastrointestinal stromal tumor.